Amgen beats expectations in 2014 and gears up for more growth
This article was originally published in Scrip
Amgen, the world's biggest biotech company, reported better-than-expected full year and fourth quarter 2014 financial results on 27 January. Revenues for 2014 increased 7% to $20.1bn while EPS increased 14% to $8.70. Estimates had put full-year revenue at $19.94bn and EPS at $8.59 (scripintelligence.com, 23 January 2015).